| Company Name: |
ShangHai Caerulum Pharma Discovery Co., Ltd.
|
| Tel: |
18149758185 18149758185; |
| Email: |
sales-cpd@caerulumpharma.com |
| Products Intro: |
Product Name:VU0453379
CAS:1638646-27-1
Purity:98% Package:10mg;100mg;1g;10g;100g;1kg
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Email: |
sales@invivochem.cn |
| Products Intro: |
Product Name:VU0453379
CAS:1638646-27-1
Purity:98% HPLC Package:1mg Remarks:V28095
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:VU0453379
CAS:1638646-27-1
Package:2mg/RMB 1710
|
VU0453379 manufacturers
- VU0453379
-
- $244.00 / 2mg
-
2026-01-04
- CAS:1638646-27-1
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | VU0453379 Basic information |
| Product Name: | VU0453379 | | Synonyms: | VU0453379;1H-Pyrido[3,4-b]indole-4-carboxamide, 2-cyclopentyl-2,9-dihydro-9-methyl-N-[[(2S)-1-(1-methylethyl)-2-pyrrolidinyl]methyl]-1-oxo- | | CAS: | 1638646-27-1 | | MF: | C26H34N4O2 | | MW: | 434.57 | | EINECS: | | | Product Categories: | | | Mol File: | 1638646-27-1.mol |  |
| | VU0453379 Chemical Properties |
| Boiling point | 671.8±55.0 °C(Predicted) | | density | 1.28±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 13.46±0.20(Predicted) | | form | Solid | | color | Off-white to light yellow | | Water Solubility | H2O: 20mg/mL, clear | | InChIKey | OCMGNMGYQPPMFF-FYZYNONXSA-N | | SMILES | CN1C2=C(C(C(NC[C@@H]3CCCN3C(C)C)=O)=CN(C4CCCC4)C2=O)C5=CC=CC=C51.Cl |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | VU0453379 Usage And Synthesis |
| Uses | VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM[1]. | | Biological Activity | VU0453379 is a highly selective CNS penetrant positive allosteric modulator of Glucagon-like peptide-1 (GLP-1) with GLP-1 EC50 = 1.3 μ,M, 59.2% GLP-1 max. VU0453379 potentiated low-dose exenatide to augment insulin secretion in primary mouse pancreatic islets. In a model of Parkinson′s disease it showed a significant reversal of haloperidol-induced catalepsy at 30 mg/kg. | | References | [1] Morris LC, et al. Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM). J Med Chem. 2014 Dec 11;57(23):10192-7. DOI:10.1021/jm501375c |
| | VU0453379 Preparation Products And Raw materials |
|